Navigation Links
Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Date:8/14/2014

tations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that we will not be able to find a partner to help conduct the Phase 3 trials for AmiKet™ on attractive terms, a timely basis or at all the risk that we will not obtain approval to market and commercialize any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; risks associated with our ability to protect our intellectual property; risks associate with our ability to raise additional funds; and our liquidity. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking
'/>"/>
SOURCE Immune Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novimmune Reports Successful Completion of Phase I trial for NI-0101
2. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
3. UMD Researcher Helps Arm the Immune System to Fight Cancer
4. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
5. BHI Elects MedImmunes Reg Seeto, M.D. to Board of Directors
6. Global Autoimmune Disease Diagnostics Market
7. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
8. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
9. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
10. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , Mar. 02, 2015 Research and Markets ... addition of the "Lopinavir - Comprehensive patent ... Imagine having your own team of ... button. Used by the world,s leading ... years, these searches are the benchmark in comprehensive, ...
(Date:3/2/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Drug Application (NDA) with the U. S. Food and Drug ... signs and symptoms of dry eye disease in adults. ... to address both the signs and symptoms of dry eye ... said Philip J. Vickers , Ph.D., Head of Research ...
(Date:3/2/2015)... , March 2, 2015 The Economist ... London last week on 26 February was host to ... on a number of topical issues facing the sector. This year,s ...   E ra , , observed the challenges the ... them. Panel speakers offered contrasting and thought-provoking commentary on ...
Breaking Medicine Technology:Global Comprehensive Lopinavir Patent Search Online Portal 2015 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 3Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 421 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 221 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 321 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 421 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 521 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 6
(Date:3/2/2015)... FL (PRWEB) March 02, 2015 While ... with Title VI of the Civil Rights Act, the ... and hearing loss are bringing light to the value ... statistics reveal that nearly 1 in 20 U.S. children ... in 10 in some major cities.(1) Stratus Video ...
(Date:3/2/2015)... Birmingham, Alabama (PRWEB) March 02, 2015 ... Alabama - In conjunction with Women in Construction Week ... in Construction, or NAWIC) and National Women’s History Month, ... and commitment positively affect the company and the construction ... the management team, to the dozens of roles in ...
(Date:3/2/2015)... 02, 2015 Over the last five ... leading vendors seeking to expand their geographic presence and ... expected to reach $6.2 billion by 2019 at CAGR ... including the U.S. and Canada and a major part ... developing regions such as Asia-Pacific including China and India, ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 ... lot easier thanks to the success of ... meal planning easy and delicious for thousands of ... positive customer feedback by expanding to offer a ... Tastes, which features seasonally appropriate classic recipes and ...
(Date:3/2/2015)... March 02, 2015 In light of ... anticoagulant Xarelto (rivaroxaban) tablets, Ford & Associates ... be helpful for future users, but may come too ... from taking the drug. The FDA has now included ... Adverse Reactions on Xarelto's label. The term “cytolytic hepatitis” ...
Breaking Medicine News(10 mins):Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:Robins & Morton Recognizes Women In Construction 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4
... Venture Team by 30%, MENLO PARK, Calif., ... ), a leading venture capital firm celebrating,40 years ... exceeded its,fundraising goal and closed its ninth fund ... firm,s total capital under management to $2.6,billion. Morgenthaler ...
... offers easy access to,personalized Part D Plan comparisons, ... As the Open,Enrollment Period for Medicare Part D ... and the National Council on Aging,(NCOA) are educating ... drug plan at the most affordable cost. Among ...
... Mothers Regarding,Protecting Children from the Flu, ... National,Association of Child Care Professionals (NACCP), Families ... Coalition (CIIC) are,launching their second annual nationwide ... seriousness of influenza in children, and increase,influenza ...
... study suggests , , WEDNESDAY, Nov. 12 (HealthDay News) -- ... those in the 1970s to believe they,ll make outstanding ... also much more likely to claim they are "A" ... shows that today,s students do less homework than their ...
... 12 As the stock market hits record lows,the nation,s ... and books on managing stress, people report being more stressed,than ... the Mind, psychologist,Bill Crawford, Ph.D., identifies why advice such as, ... can make the problem worse., This problem is explained ...
... Gulian to speak at ID WORLD International Conference on Wireless ... ... IFLG ), a leading provider of enterprise mobility and advanced,wireless ... David Gulian, president and CEO, will,present on the predictive value of ...
Cached Medicine News:Health News:Morgenthaler Closes Ninth Fund at $400 Million 2Health News:Morgenthaler Closes Ninth Fund at $400 Million 3Health News:Morgenthaler Closes Ninth Fund at $400 Million 4Health News:Video: CVS/pharmacy and National Council on Aging Help Seniors to Find the Right 'Prescription' for Medicare Savings 2Health News:Video: CVS/pharmacy and National Council on Aging Help Seniors to Find the Right 'Prescription' for Medicare Savings 3Health News:NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 2Health News:NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 3Health News:NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 4Health News:NACCP, Families Fighting Flu, and the Childhood Influenza Immunization Coalition Team Up to Educate Families About Annual Childhood Flu Vaccination 5Health News:U.S. Teens Brimming With Self-Esteem 2Health News:U.S. Teens Brimming With Self-Esteem 3Health News:U.S. Teens Brimming With Self-Esteem 4Health News:Stress Spikes as Economy Tanks - Psychologist Identifies Why Traditional 'Stress Management' Techniques Don't Work, and Offers Radical New Approach 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 3
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: